Clinical Trial

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Study acronym: ReSPECT-LM
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 26, 2025 (before its estimated December 21, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-08-30; most recent amendment 2025-03-25.
Status change: Recruiting → Active, Not Recruiting 2025-03-25
Status change: Not Yet Recruiting → Recruiting 2021-12-28
Trial Details
NCT Number NCT05034497
Lead Sponsor Plus Therapeutics
Conditions Leptomeningeal Metastasis
Enrollment 18 participants
Start Date 2021-12-06
Primary Completion 2025-12-21 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-26